Drug Notebook

FDA Alerts

    Infusion-related Effects
  • Severe infusion-related effects (rarely fatal) reported in about 3% of patients. May occur after any dose; however, approximately 90% of reported cases occurred during first infusion despite premedication with antihistamines.
  • Manifested as rapid airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, and/or cardiac arrest.
  • Monitor patients during and for 1 hour following each infusion. If severe infusion-related effects occur, discontinue cetuximab immediately and permanently. (See Infusion-related Effects under Cautions.)
    Cardiopulmonary Arrest
  • Cardiopulmonary arrest and/or sudden death reported in 2% of patients with squamous cell carcinoma of the head and neck receiving cetuximab in combination with radiation therapy in one study. (See Cardiopulmonary Arrest under Cautions.) Fatal events occurred within 1–43 days after last cetuximab dose. Etiology of these events is unknown.
  • Caution in patients with head and neck cancer who have history or clinical evidence of CAD, CHF, or arrhythmias. Closely monitor serum electrolytes (including magnesium, potassium, and calcium) during and after cetuximab therapy.

Drug Info Tools
Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
Licensed from
cetuximab
Page: 1 2 3 Next >
(seh TUX ih mab)

What is the most important information I should know about cetuximab?

You should not use this medication if you are allergic to cetuximab or to mouse protein.

Before receiving cetuximab, tell your doctor if you have heart rhythm problems, congestive heart failure, breathing problems, or coronary artery disease. Tell your doctor if you are also being treated with cisplatin (Platinol).

After you receive this medicine, your doctor will need to watch you for about an hour. This is to make sure you do not have any serious side effects from the medicine.

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseated, itchy, or have wheezing, noisy breathing, or a hoarse voice during the injection.

To be sure this medication is helping your condition and not causing harmful effects, your blood will need to be tested on a regular basis. It is important that you not miss any scheduled visits to your doctor. You may need to have blood tests for several weeks after your cetuximab treatment has ended.

Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds) while you are receiving cetuximab and for at least 2 months after your treatment ends. Cetuximab can make your skin more sensitive to sunlight and sunburn may result. Use a sunscreen (minimum SPF 15) and wear protective clothing if you must be out in the sun.

What is cetuximab?

Cetuximab is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.

Cetuximab is used to treat cancers of the colon and rectum. It is also used to treat head and neck cancer.

Cetuximab may also be used for other purposes not listed in this medication guide.

Page: 1 2 3 Next >
Related Learning
Centers
Advertisement
Back to Top